undergoing at Biology Products
undergoing at Biology Technology
undergoing at Medicine News
Antioxidants protect health tissue in people undergoing radiation therapy.
A recent finding by Indian scientists revealed that two antioxidants in black pepper and turmeric- piperine and curcumin were found to help protect the bacterial DNA from damage by irradiation in test organism. Spices with antioxidants property have radio protective effect and protecting organisms like Escherichia role and Bacillus megaterium organisms (taken for study) against of gamma...
Avoid Coffee Before Undergoing PET/ CT scans
Researchers at Saint Louis University have suggested that patients going for PET or CT scan should avoid // drinking coffee as caffeine intake interferes with PET/CT image results when there is a known or suspected cancers, Dr. Osman from the university presented his study that looks at the relationship between caffeine intake and uptake by the hear of the tracer used in the PET scan c...
AIDS Drug Found To Help Patients Undergoing Chemotherapy
Researchers say they discovered an anti-viral drug that helps reduce the risk of reactivating the hepatitis B virus in women who are being treated with chemotherapy for breast cancer.An estimated 12 percent // of breast cancer patients carry the hepatitis B virus and these patients are at risk of developing HBV reactivation during chemotherapy, which is a well-known complication resulting...
Cryopreservation of Ovaries for Cancer patients undergoing treatment
Researchers from Israel has found a new method of Cryopreservation of ovaries for few years and then reimplanting them into the same women. The procedure would be very useful for women with cancer, because during cancer // hormonal treatment, the chances of women getting infertile is very high. This method involves removing the ovaries then freezing them till required, when the treatment...
Women Compensated For Losing Eye-Sight After Undergoing Cataract Operation
The District Consumer Redressal forum ordered a compensation of Rs one lakh each to two women who lost their eye-sight after
undergoing cataract operation// at a free medical Camp conducted on behalf of the Theni District Administration on January 24, 2003. The women submitted that after they underwent the operation at the Periyakulam Government Hospital,they developed severe pain and l...
More>>
undergoing at Medicine Products
undergoing at Medicine Technology
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients
undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...
Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical
Data for INO-1001 at ACC Demonstrating PARP Inhibition and
Anti-inflammatory Activity in Plasma of Patients Undergoing Primary
Percutaneous Coronary Intervention
BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - InotekPharmaceuticals Corporation announced today the presentation ofpositive Phase 2 clinical data demonstrating the safety of INO-1001as well as the potential for INO-1001 as a preventative agent forcardiac reperfusion injury. The study was conducted in subjectswith acute ST-elevated myocardial infarction (STEMI)
undergoingprimary percutaneo...
MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study
of Aquavan Injection in Patients Undergoing Bronchoscopy
MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC.(NASDAQ: MOGN), a biopharmaceutical company focused in oncology andacute care, today announced that a randomized, double-blind,multi-center, pivotal phase 3 trial of Aquavan(R) (fospropofoldisodium) Injection for sedation of patients
undergoingbronchoscopy successfully met its primary endpoint of sedationsuccess as well as all sec...